![Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin](https://www.e-crt.org/upload//thumbnails/crt-2018-326f1.jpg)
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
![Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | British Journal of Cancer Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6605779/MediaObjects/41416_2010_Article_BF6605779_Fig1_HTML.jpg)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | British Journal of Cancer
![Figure 1 from Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. | Semantic Scholar Figure 1 from Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0bdef4bfb8f9c0f0dcbe0be51e9934eea0a7fbc3/4-Figure1-1.png)
Figure 1 from Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. | Semantic Scholar
![Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple ... Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple ...](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-020-6610-4/MediaObjects/12885_2020_6610_Fig1_HTML.png)
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple ...
![Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan](https://journals.sagepub.com/cms/10.1177/17588359211035983/asset/images/large/10.1177_17588359211035983-fig1.jpeg)
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan
![Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III ... Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III ...](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-015-1498-0/MediaObjects/12885_2015_1498_Fig1_HTML.gif)
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III ...
![Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer - ScienceDirect Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2090123221002599-ga1.jpg)
Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer - ScienceDirect
European Urology on X: "Best of 2020 Visual Abstracts 4th Place #VisualAbstract Randomized Phase III Trial of ddMVAC, and Cis, or Gem/Cis as Perioperative Chemotherapy for Pts with MIBC. Analysis of the
![Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial - ScienceDirect Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500206000602-gr1.jpg)
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial - ScienceDirect
![PDF] Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma. | Semantic Scholar PDF] Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fe13e465c76638e4a3776bdf6e5839d9ed983703/2-Figure1-1.png)
PDF] Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma. | Semantic Scholar
![Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial - The Lancet Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/2068290708/2067302393/gr1.gif)
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial - The Lancet
![Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer | Journal of Urology Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer | Journal of Urology](https://www.auajournals.org/cms/asset/6c88e145-f5f0-4e04-9616-a9612536b144/abs-fig.jpg)
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer | Journal of Urology
![VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma | 2 Minute Medicine VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2022/09/2MM-VA-9.18.2022_NPC_Gemcitabine_Cisplatin-scaled.jpg)